Patent ID: 7666405

Claim:
A pharmaceutical composition comprising a propagation-defective adenovirus in a pharmaceutically acceptable carrier, wherein said adenovirus comprises an adenovirus genome comprising: (a) a heterologous nucleotide sequence encoding a lysosomal acid α-glucosidase precursor; (b) one or more deletions in the E1 region, wherein said deletion(s) essentially prevents the expression of one or more functional E1 proteins from said deleted region; and (c) one or more deletions in the polymerase region, wherein said deletion(s) essentially prevents the expression of a functional polymerase protein from said deleted region, and wherein the lysosomal acid α-glucosidase precursor is expressed from the propagation-defective adenovirus after administration of the pharmaceutical composition to a mammalian subject and is secreted, resulting in a reduction in lysosomal glycogen stores in muscle tissue.